Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.

por Hug, V., Kau, S., Hortobagyi, G. N., Jones, L.
Publicado 1991

Clonogenic growth and hormone sensitivity of benign and malignant breast tissues.

por Hug, V., Rashid, R., Johnston, D., Hortobagyi, G.
Publicado 1987

A unified definition of clinical anthracycline resistance breast cancer

por Pivot, X, Asmar, L, Buzdar, A U, Valero, V, Hortobagyi, G
Publicado 2000

Improved culture conditions for clonogenic growth of primary human breast tumours.

por Hug, V., Haynes, M., Rashid, R., Spitzer, G., Blumenschen, G., Hortobagyi, G.
Publicado 1984

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins

por Smith, B L, Chin, D, Maltzman, W, Crosby, K, Hortobagyi, G N, Bacus, S S
Publicado 2004

Reply: Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria

por Hamaoka, T, Costelloe, C M, Madewell, J E, Liu, P, Hortobagyi, G N, Ueno, N T
Publicado 2010

PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin

por Lee, J, Bartholomeusz, C, Krishnamurthy, S, Liu, P, Saso, H, LaFortune, T A, Hortobagyi, G N, Ueno, N T
Publicado 2012

Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers

por Mazouni, C, Arun, B, André, F, Ayers, M, Krishnamurthy, S, Wang, B, Hortobagyi, G N, Buzdar, A U, Pusztai, L
Publicado 2008

Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity

por Reddy, S M, Barcenas, C H, Sinha, A K, Hsu, L, Moulder, S L, Tripathy, D, Hortobagyi, G N, Valero, V
Publicado 2018

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

por Hamaoka, T, Costelloe, C M, Madewell, J E, Liu, P, Berry, D A, Islam, R, Theriault, R L, Hortobagyi, G N, Ueno, N T
Publicado 2010

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas

por Delpech, Y, Coutant, C, Hsu, L, Barranger, E, Iwamoto, T, Barcenas, C H, Hortobagyi, G N, Rouzier, R, Esteva, F J, Pusztai, L
Publicado 2013

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

por Rugo, H. S., Hortobagyi, G. N., Yao, J., Pavel, M., Ravaud, A., Franz, D., Ringeisen, F., Gallo, J., Rouyrre, N., Anak, O., Motzer, R.
Publicado 2016

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy

por Gonzalez-Angulo, A M, Parinyanitikul, N, Lei, X, Mittendorf, E A, Zhang, H, Valero, V, Hunt, K K, Hortobagyi, G N, Chavez-MacGregor, M
Publicado 2015

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients

por Cheng, Y C, Valero, V, Davis, M L, Green, M C, Gonzalez-Angulo, A M, Theriault, R L, Murray, J L, Hortobagyi, G N, Ueno, N T
Publicado 2010

Statin use in primary inflammatory breast cancer: a cohort study

por Brewer, T M, Masuda, H, Liu, D D, Shen, Y, Liu, P, Iwamoto, T, Kai, K, Barnett, C M, Woodward, W A, Reuben, J M, Yang, P, Hortobagyi, G N, Ueno, N T
Publicado 2013

A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes

por Dutta, B, Pusztai, L, Qi, Y, André, F, Lazar, V, Bianchini, G, Ueno, N, Agarwal, R, Wang, B, Shiang, C Y, Hortobagyi, G N, Mills, G B, Symmans, W F, Balázsi, G
Publicado 2012

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

por Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., Chouinard, E., Srimuninnimit, V., Puttawibul, P., Eakle, J., Feng, W., Bauly, H., El-Hashimy, M., Taran, T., Burris, H. A.
Publicado 2014

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) r...

por Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H. R., Corso, S. W., Lew, D. L., Pusztai, L., Livingston, R. B., Hortobagyi, G. N.
Publicado 2016

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breas...

por Hortobagyi, G N, Stemmer, S M, Burris, H A, Yap, Y S, Sonke, G S, Paluch-Shimon, S, Campone, M, Petrakova, K, Blackwell, K L, Winer, E P, Janni, W, Verma, S, Conte, P, Arteaga, C L, Cameron, D A, Mondal, S, Su, F, Miller, M, Elmeliegy, M, Germa, C, O’Shaughnessy, J
Publicado 2019